Suppressed expression of CD44 variant isoforms during human glioma A172 cell differentiation induced by cyclic AMP

Neurosci Lett. 1996 Jun 7;210(3):189-92. doi: 10.1016/0304-3940(96)12683-5.

Abstract

CD44 is a major receptor for hyaluronic acid, which is the most frequent route of malignant glioma invasion. Multiple isoforms of CD44 are generated by alternative mRNA splicing. We have examined differential expression of CD44 variant isoforms (CD44vs) during dibutyryl cyclic AMP (dbcAMP)/theophylline-induced differentiation of human glioma A172 cells using reverse transcriptase-polymerase chain reaction (RT-PCR). Treatment of cells with dbcAMP and theophylline caused decreased expression of all CD44 isoforms after 24 h. The CD44 standard form was observed to return to the unstimulated level after 72 h, whereas the variant isoforms, CD44 8v-10v and 10v, remained at the low level after 24-72 h. Changes of CD44vs were correlated with the level of expression of c-jun. These results suggested that the expression patterns of CD44vs might correlate with cellular differentiation in human glioma cells.).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms / metabolism*
  • Bucladesine / pharmacology
  • Cell Differentiation / physiology
  • Cyclic AMP / physiology*
  • Glioma / metabolism*
  • Humans
  • Hyaluronan Receptors / biosynthesis*
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins c-jun / biosynthesis
  • RNA, Messenger / biosynthesis
  • Theophylline / pharmacology
  • Tumor Cells, Cultured

Substances

  • Hyaluronan Receptors
  • Proto-Oncogene Proteins c-jun
  • RNA, Messenger
  • Bucladesine
  • Theophylline
  • Cyclic AMP